885276-95-9 Usage
Uses
Used in Pharmaceutical Research:
3-IODO-IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID METHYL ESTER is used as a building block for the synthesis of various heterocyclic compounds, which are essential in the development of new pharmaceutical agents. Its unique structure allows for the creation of diverse chemical entities with potential therapeutic applications.
Used in Chemical Research:
In the field of chemical research, 3-IODO-IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID METHYL ESTER serves as a valuable intermediate for the synthesis of complex organic molecules. Its reactivity and structural features make it a promising candidate for further exploration and development in organic chemistry.
Used in Biological Activity Studies:
3-IODO-IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID METHYL ESTER is used as a subject of study for its potential biological activities, particularly as an inhibitor of kinase enzymes. This application is crucial in understanding its role in biological processes and its potential as a therapeutic agent in treating diseases associated with kinase dysregulation.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, 3-IODO-IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID METHYL ESTER holds promise for future discovery and development. Its exploration is ongoing, with the aim of identifying its precise properties and uses, which could lead to the creation of novel drugs and therapeutic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 885276-95-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,2,7 and 6 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 885276-95:
(8*8)+(7*8)+(6*5)+(5*2)+(4*7)+(3*6)+(2*9)+(1*5)=229
229 % 10 = 9
So 885276-95-9 is a valid CAS Registry Number.
885276-95-9Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
-
, (2011/06/11)
Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).
